Tag: Patisiran

Antisense RNA

Neurological disorders

Ionis Pharmaceuticals

AstraZeneca

Click the tags to see associated articles and topics

View Article Details

AstraZeneca picks up new weapon in rare disease fight with Alnylam and Pfizer, paying $30 ...

Added to Collection on: 2022-01-07 18:33:32

Tags for this article:

Life Sciences

Health care

Health sciences

Oxford–AstraZeneca COVID-19 vaccine

RNA interference

Orphan drugs

AstraZeneca

Click the tags to see associated articles and topics

View Article Details

Alnylam, awaiting key study data, builds case for its next rare disease drug | BioPharma Dive

Added to Collection on: 2022-01-21 17:21:21

Tags for this article:

Ionis Pharmaceuticals

Transthyretin

Click the tags to see associated articles and topics

View Article Details

Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View - April 29, 2022 - Zacks

Added to Collection on: 2022-04-29 16:44:02

Tags for this article:

Regeneron Pharmaceuticals

Lumasiran

Small interfering RNA

Novartis

Alnylam Pharmaceuticals Inc.

Click the tags to see associated articles and topics

View Article Details

Alnylam follows rivals with new study results for kidney disease drug - BioPharma Dive

Added to Collection on: 2022-06-09 16:25:59

Tags for this article:

Click the tags to see associated articles and topics

View Article Details

Alnylam's 5th Drug Launches in July, Disrupting Commercial Landscape - TheStreet

Added to Collection on: 2022-07-01 17:34:07

Tags for this article:

RNA interference

Alnylam Pharmaceuticals Inc.

Intellia Therapeutics

Click the tags to see associated articles and topics

View Article Details

Alnylam drug succeeds in key heart disease study, boosting company | BioPharma Dive

Added to Collection on: 2022-08-03 11:44:28

Tags for this article:

Design of experiments

Placebo

Clinical trial

Click the tags to see associated articles and topics

View Article Details

Alnylam details anticipated results from heart disease drug trial - BioPharma Dive

Added to Collection on: 2022-09-08 07:51:08

Tags for this article:

Health

Branches of biology

Medicine

Clinical research

Neurological disorders

Transthyretin

Placebo

Click the tags to see associated articles and topics

View Article Details

Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10% - February 16, 2024

Added to Collection on: 2024-02-16 17:03:48

Tags for this article:

Small interfering RNA

Orphan drugs

RNA

Molecular genetics

RNA interference

Regeneron Pharmaceuticals

Vutrisiran

Alnylam Pharmaceuticals Inc.

Click the tags to see associated articles and topics

View Article Details

The Manufacturers Life Insurance Company Sells 137,655 Shares of Alnylam ... - MarketBeat

Added to Collection on: 2024-11-29 09:54:14

Tags for this article:

Equity securities

Stock market